Philipp Backhaus, Samuele Cazzamalli, Sebastian Oehler, Florian Büther, Julia Brosch-Lenz, Felicitas Landau, Hans‐Jörg Breyholz, M. Claesener, Francesca Migliorini, Andrea Ciamarone, Tony Georgiev, Jacqueline Mock, David Ventura, Cristina Barca, Lars Schiefelbein, Sven Hermann, Klaus Schäfers, Florian Gierse, Christof Bernemann, Katrin Schlack, Martin Bögemann, Emanuele Puca, Philipp Schindler, Dario Neri, Kambiz Rahbar, Andres Jan Schrader, Konstantin Egon Seifert, Michael Schäfers
Ga]Ga-OncoACP3-DOTA changed therapeutic management in three of six patients with biochemical recurrence, and in two of 12 patients with known metastases. Although the retrospective comparison is potentially biased, the intense and reliable tumor uptake and the low off-target activity of OncoACP3-DOTA provide a strong rationale for future exploration in trials on PET imaging and radioligand therapy with β- and α-particle emitters.